Screening Pathology analysis is accurate and 3.11 Analysis of screening test is in accordance with the Program completed to Program quality and test manufacturer’s requirements and within the timeframes specifications. agreed between the contracted service provider and Health. 3.12 The contracted laboratory and its services for the Program comply with all relevant accreditation, quality and contractual requirements. The screening test and its analysis are effective, safe and acceptable; 3.13 Test results are provided to and effective screening is participants and GPs (where nominated) supported by appropriate program within five days from the analysis of the design test at the laboratory. 3.14 Test result letters provide information to participants and GPs on the actions recommended for a positive or a negative test result, and for progression along the Screening Pathway.
Screening The screening test and its analysis are effective, safe and acceptable; and effective screening is supported by appropriate program design Pathology analysis is accurate and in accordance with the Program and test manufacturer’s specifications. 3.11 Analysis of screening test is completed to Program quality requirements and within the timeframes agreed between the contracted service provider and Health. 3.12 The contracted laboratory and its services for the Program comply with all relevant accreditation, quality and contractual requirements. 3.13 Test results are provided to participants and GPs (where nominated) within five days from the analysis of the test at the laboratory. 3.14 Test result letters provide information to participants and GPs on the actions recommended for a positive or a negative test result, and for progression along the Screening Pathway.
20170329%20NBCSP%20Quality%20Framework%20V1.0%20Endorsed%20by%20SCoS%20and%20Published%20Finalised.docx